Company: MIRA
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001183
Chunk: 908

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 8
Chunk 908
---
    Net
    cash used in operating activities 
    $(5,560,606) 
    $(4,532,403)

    Financing
    activities: 

    Deferred
    offering costs 
     -  
     143,427 
  
    Repayments
    under related party line of credit 
     -  
     (1,142,483)
  
    Advances
    from (to) affiliates 
     33,713  
     (69,152)
  
    Advances
    received from related party line of credit 
     -  
     2,147,920 
  
    Bayshore
    Trust short-swing disgorgement 
     148,703  
     - 
  
    Proceeds
    from sale of common stock, less offering costs 
     3,608,555  
     7,704,279 
  
    Net
    cash provided by financing activities 
    $3,790,971  
    $8,783,991 

    Net
    increase (decrease) in cash  
     (1,769,635) 
     4,251,588 
  
    Cash,
    beginning of year 
     4,602,566  
     350,978 
  
    Cash,
    end of year 
    $2,832,931  
    $4,602,566 

    Supplemental
    disclosure of cash flow information 

    Cash
    paid for interest 
    $-  
    $- 
  
    Cash
    paid for income taxes 
    $-  
    $- 
  
    Supplemental
    schedule of non-cash financing activities: 

    Deferred
    offering costs charged to additional paid-in capital 
    $32,500  
    $426,345 

See
notes to consolidated financial statements

F-7

MIRA
PHARMACEUTICALS, INC.

SUPPLEMENTAL
CASH FLOW INFORMATION

Non-cash
financing and investing activities:

The
Company recorded deferred offering costs of $32,500 during the year ended December 31, 2024 in association with the At the Market Agreement
and charged these costs to additional paid in capital.

The
Company recorded the fair value of a total of 1,000,000 shares of common stock issued to Bay Shore Trust during the year ended December
31,